Abstract
To compare the costs of administering oral paclitaxel (oral-p) compared to IV paclitaxel (IV-p) as a second-line therapy for patients with advanced gastric cancer from a limited societal perspective in a South Korean environment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
